Get the Stockscreener App
1.19
0.85%
0.01
Iridex Corp stock is traded at $1.19, with a volume of 15,382.
It is up +0.85% in the last 24 hours and up +26.56% over the past month.
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
See More
Previous Close:
$1.18
Open:
$1.2
24h Volume:
15,382
Relative Volume:
0.20
Market Cap:
$20.46M
Revenue:
$48.43M
Net Income/Loss:
$-11.04M
P/E Ratio:
-1.7761
EPS:
-0.67
Net Cash Flow:
$-7.00M
1W Performance:
+4.39%
1M Performance:
+26.56%
6M Performance:
+25.26%
1Y Performance:
-33.89%
1-Day Range:
$1.19
$1.20
1-Week Range:
$1.13
$1.2291
52-Week Range:
$0.782
$1.80
Iridex Corp Stock (IRIX) Company Profile
Name
Iridex Corp
Sector
Industry
Phone
(650) 940-4700
Address
1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA
Compare IRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRIX
Iridex Corp
|
1.19 | 20.28M | 48.43M | -11.04M | -7.00M | -0.67 |
|
ABT
Abbott Laboratories
|
127.04 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.65 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.75 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.77 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.83 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Iridex Corp Stock (IRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-17 | Resumed | ROTH Capital | Buy |
| Dec-21-16 | Initiated | ROTH Capital | Buy |
| Jan-26-16 | Initiated | Singular Research | Buy |
| Jan-03-07 | Initiated | First Albany | Buy |
Iridex Corp Stock (IRIX) Latest News
IRIDEX Corp: Can This Beaten-Down Ophthalmic Stock Still See The Light? - AD HOC NEWS
IRIDEX (NASDAQ:IRIX) Shares Cross Below 200-Day Moving Average – What’s Next? - Defense World
IRIX SEC FilingsIridex 10-K, 10-Q, 8-K Forms - Stock Titan
Is IRIDEX Corporation stock a top momentum playJuly 2025 Macro Moves & Daily Stock Momentum Reports - Улправда
Published on: 2025-12-19 17:58:41 - Улправда
What margin trends mean for IRIDEX Corporation stockJuly 2025 Catalysts & Reliable Volume Spike Trade Alerts - Улправда
[Form 4] IRIDEX CORP Insider Trading Activity - Stock Titan
Why retail investors pile into IRIDEX Corporation stockRisk Management & High Conviction Investment Ideas - Улправда
IRIDEX (IRIX) director William Moore reports 20,000-share stock purchase - Stock Titan
Iridex CFO Dizon buys $2296 in company stock By Investing.com - Investing.com Nigeria
I’ve reviewed the SEC filing and prepared the following news article - Investing.com UK
Dir Moore Buys 30,000 ($28.5K) Of IRIDEX Corp [IRIX] - TradingView — Track All Markets
Iridex CFO Dizon buys $2296 in company stock - Investing.com
IRIDEX Corporation (NASDAQ: IRIX) presents at Sidoti Year-End Virtual Investor Conference - Stock Titan
Iridex study shows MicroPulse laser retreatment effective for glaucoma - Investing.com
Iridex study shows MicroPulse laser retreatment effective for glaucoma By Investing.com - Investing.com Canada
Iridex Corporation Announces Positive Findings on MicroPulse Technology for Glaucoma Retreatment in Independent Study - Quiver Quantitative
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management - The Manila Times
Iridex (IRIX) Reveals Study on Laser Treatments for Glaucoma - GuruFocus
Iridex Corporation Announces Publication of Study on Thermal Dynamics of Laser Treatments for Glaucoma - Quiver Quantitative
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment - marketscreener.com
Iridex (NASDAQ: IRIX) publishes thermal modeling study on MicroPulse vs CW glaucoma lasers - Stock Titan
Iridex (Nasdaq: IRIX) sets Dec. 11 slot at Sidoti virtual investor conference - Stock Titan
Is IRIDEX Corporation stock vulnerable to regulatory risksJuly 2025 Action & AI Enhanced Trading Signals - Newser
Iridex (IRIX) Stock Analysis Report | Financials & Insights - Benzinga
Iridex CFO Dizon buys $5529 in company stock By Investing.com - Investing.com Australia
Iridex CFO Dizon buys $5529 in company stock - Investing.com India
Iridex CFO Dizon buys $960 in company stock By Investing.com - Investing.com South Africa
Iridex CFO Dizon buys $960 in company stock - Investing.com
Will IRIDEX Corporation stock keep outperforming rivals2025 Key Highlights & Safe Entry Zone Tips - newser.com
Iridex CFO Dizon buys $2k in company stock By Investing.com - Investing.com Nigeria
Iridex CFO Dizon buys $2k in company stock - Investing.com
How IRIDEX Corporation stock reacts to global recession fears2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Why IRIDEX Corporation stock is a must watch in 2025Weekly Market Outlook & Low Volatility Stock Recommendations - newser.com
Iridex director Moore buys shares worth $48,331 By Investing.com - Investing.com Australia
Iridex CFO Dizon buys shares worth $2998 By Investing.com - Investing.com Nigeria
Iridex director Moore buys shares worth $48,331 - Investing.com India
Iridex Corp Stock (IRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iridex Corp Stock (IRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dizon Romeo R | Chief Financial Officer |
Dec 12 '25 |
Buy |
0.97 |
2,365 |
2,296 |
92,685 |
| Dizon Romeo R | Chief Financial Officer |
Dec 02 '25 |
Buy |
0.95 |
1,584 |
1,498 |
90,320 |
| Dizon Romeo R | Chief Financial Officer |
Nov 20 '25 |
Buy |
0.96 |
5,760 |
5,530 |
88,736 |
| Dizon Romeo R | Chief Financial Officer |
Nov 19 '25 |
Buy |
0.96 |
1,000 |
960 |
82,976 |
| Dizon Romeo R | Chief Financial Officer |
Nov 18 '25 |
Buy |
0.94 |
2,133 |
2,005 |
81,976 |
| MOORE WILLIAM M | Director |
Nov 14 '25 |
Buy |
0.97 |
28,157 |
27,245 |
228,831 |
| MOORE WILLIAM M | Director |
Nov 17 '25 |
Buy |
0.97 |
21,843 |
21,087 |
250,674 |
| Dizon Romeo R | Chief Financial Officer |
Nov 17 '25 |
Buy |
0.96 |
3,124 |
2,999 |
79,843 |
| Dizon Romeo R | Chief Financial Officer |
Nov 14 '25 |
Buy |
0.88 |
14,769 |
12,997 |
76,719 |
| Dizon Romeo R | Chief Financial Officer |
Sep 12 '25 |
Buy |
1.36 |
1,450 |
1,975 |
61,950 |
1.64%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):